{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:37:02Z","timestamp":1784601422852,"version":"3.55.0"},"reference-count":12,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Saudi Med"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Respiratory syncytial virus (RSV) is a viral pathogen that causes annual epidemics of lower respiratory tract infection with substantial morbidity and mortality in young children, especially those with congenital heart disease (CHD). Palivizumab is the only immunoprophylaxis therapy approved for RSV infection in infants with hemodynamically significant acyanotic or cyanotic CHD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>Identify the compliance rate with vaccination and study the effect of RSV vaccination on hospital admissions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective descriptive study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Cardiac center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS:<\/jats:title>\n            <jats:p>Patient data was obtained from outpatient clinic records, inpatient records, and a surgical database for the period from October 2010 to March 2016. Infants with hemodynamically significant CHD, cyanotic CHD and moderate-to-severe pulmonary hypertension were included in the study. Palivizumab 15\/mg\/kg was given monthly starting from October, the usual beginning of the epidemic season, with five doses in the first season and six doses in the remaining season scheduled for administration. Patients were interviewed at every clinic visit for any side effects during the previous month, occurrence of any RSV infection and any hospital admission. Selection criteria included RSV vaccination and absence of RSV disease. Patients were excluded if they had RSV infection or a repaired cardiac lesion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n            <jats:p>Compliance rate, hospital admission frequency and period of stay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SAMPLE SIZE:<\/jats:title>\n            <jats:p>530 during six seasons of RSV epidemics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Fourteen patients (2.6%) developed RSV infection and 13 (2.5%) required hospital admission, but only one patient (0.1%) needed intensive care admission. There were no deaths related to RSV infection; however 11 patients died due to causes unrelated to RSV infection. The average compliance rate was 97%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Palivizumab was well tolerated and effective in the prophylaxis of severe RSV infection in children with CHD. As in other studies of palivizumab prophylaxis, we observed a reduction in hospital admissions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LIMITATIONS:<\/jats:title>\n            <jats:p>Retrospective design.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONFLICT OF INTEREST:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>","DOI":"10.5144\/0256-4947.2021.31","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:07:25Z","timestamp":1612818445000},"page":"31-35","source":"Crossref","is-referenced-by-count":6,"title":["Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease"],"prefix":"10.5144","volume":"41","author":[{"given":"Mohammed Hassan A.","family":"Mohammed","sequence":"first","affiliation":[{"name":"From the Department of Pediatric Cardiology, Cardiac Science, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihab","family":"Agouba","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Cardiology, Cardiac Science, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam El","family":"Obaidy","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Cardiology, Cardiac Science, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alhabshan","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Cardiology, Cardiac Science, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8614-7411","authenticated-orcid":true,"given":"Riyadh","family":"Abu-Sulaiman","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Cardiology, Cardiac Science, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3134","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.5.17-00284"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1542\/pir.35-12-519"},{"issue":"48","key":"e_1_3_2_4_2","first-page":"1133","article-title":"Respiratory syncytial virus\u2014United States, July 2012-June 2014 [published correction appears in MMWR Morb Mortal Wkly Rep. 2014;63(49):1181]","volume":"63","author":"Haynes AK","year":"2014","unstructured":"Haynes AK, Prill MM, Iwane MK, Gerber SI; Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus\u2014United States, July 2012-June 2014 [published correction appears in MMWR Morb Mortal Wkly Rep. 2014;63(49):1181]. MMWR Morb Mortal Wkly Rep. 2014; 63(48):1133\u20131136.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.92"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936113497202"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00040211"},{"issue":"4","key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"00751","DOI":"10.1128\/genomeA.00751-16","article-title":"Human Rhinovirus B and C Genomes from Rural Coastal Kenya","volume":"4","author":"Agoti CN","year":"2016","unstructured":"Agoti CN, Kiyuka PK, Kamau E, Munywoki PK, Bett A, van der Hoek L, et al. Human Rhinovirus B and C Genomes from Rural Coastal Kenya. Genome Announc. 2016 Jul 28; 4 (4):00751\u201316.","journal-title":"Genome Announc"},{"issue":"5","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes TF","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. The Journal of Pediatrics. 2003 Oct; 143 (5): 532\u2013540.","journal-title":"The Journal of Pediatrics"},{"issue":"6","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1542\/peds.2009-2681","article-title":"The 2009 COID Recommendations for RSV Prophylaxis: Issues of Efficacy, Cost, and Evidence-Based Medicine","volume":"124","author":"Krilov LR","year":"2009","unstructured":"Krilov LR, Weiner LB, Yogev R, Fergie J, Katz BZ, Henrickson KJ, et al. The 2009 COID Recommendations for RSV Prophylaxis: Issues of Efficacy, Cost, and Evidence-Based Medicine. Pediatrics. 2009 Dec; 124 (6):1054\u20131063.","journal-title":"Pediatrics"},{"issue":"2","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"RSV Policy Statement\u2014Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection","volume":"134","author":"American Academy of Pediatrics","year":"2014","unstructured":"American Academy of Pediatrics. RSV Policy Statement\u2014Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics. 2014; 134(2):415\u2013420.","journal-title":"Pediatrics."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Paes B Mitchell I Li A Harimoto T Lanctot KL. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for Palivizumab (2005-2012) compared to other international registries. 2013; 2013:917068.","DOI":"10.1155\/2013\/917068"},{"issue":"1","key":"e_1_3_2_13_2","first-page":"46","article-title":"A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis","volume":"16","author":"Frogel MP","year":"2010","unstructured":"Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010 Jan-Feb; 16(1):460-58.","journal-title":"J Manag Care Pharm"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T05:20:26Z","timestamp":1697692826000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2021.31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.5144\/0256-4947.2021.31"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2021.31","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}